Accuray is a radiation therapy company that develops, manufactures, and sells radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It is the developer of innovative technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, the latest generation TomoTherapy platform. The company is headquartered in Sunnyvale, CA, the United States. The platforms are installed in leading healthcare centres in approximately 50 countries globally.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ARAY | ACCURAY INC | 2025-10-28 15:32:07 | 1.48 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARAY | 0001138723 | ACCURAY INC | US0043971052 | 549300G28LY4TZKZJG51 | 208370041 | Nasdaq | 3841 | Surgical & Medical Instruments & Apparatus | 0630 | DE | 1240 DEMING WAY | MADISON | WI | 53717 | UNITED STATES | US | 608-824-2800 | 1240 DEMING WAY, MADISON, WI, 53717 | 1240 DEMING WAY, MADISON, WI, 53717 | — | — | 1992 | — | — | — | 146,769,044 | 112,643,852 | 112,677,147 | Accuray is a radiation therapy company that develops, manufactures, and sells radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It is the developer of innovative technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, the latest generation TomoTherapy platform. The company is headquartered in Sunnyvale, CA, the United States. The platforms are installed in leading healthcare centres in approximately 50 countries globally. | 2025-10-23 15:47:24 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 146,769,044 | -193,993,754,956 | -99.9244 | 112,677,147 | 12,409,247 | 12.3761 |
| 2024 | 194,140,524,000 | 31,073,733,000 | 19.0558 | 100,267,900 | 3,677,867 | 3.8077 |
| 2023 | 163,066,791,000 | 162,701,387,454 | 44,526.4939 | 96,590,033 | 3,090,533 | 3.3054 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Sandeep Chalke | Chief Commercial Officer, Senior Vice President | 2025 | 491,458 | 0 | 673,206 | 25,000 | 9,670 | 1,199,334 |
| Jesse Chew | Chief Legal Officer, Corporate Secretary, Senior Vice President | 2025 | 473,088 | 50,000 | 836,250 | 0 | 9,074 | 1,368,412 |
| Suzanne Winter | Chief Executive Officer, President | 2025 | 695,264 | 0 | 2,314,147 | 25,000 | 7,708 | 3,042,119 |
| Ali Pervaiz | Chief Financial Officer, Senior Vice President | 2025 | 452,333 | 0 | 589,055 | 50,000 | 6,525 | 1,097,913 |
| Suzanne Winter | Chief Executive Officer, President | 2024 | 725,000 | 0 | 2,708,486 | 72,500 | 10,053 | 3,516,039 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 990 |
| 2024 | 987 |
| 2023 | 1,024 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 458,505,000 | 446,551,000 | 447,605,000 |
| Cost Of Revenue | 311,538,000 | 303,630,000 | 293,645,000 |
| Gross Profit | 146,967,000 | 142,921,000 | 153,960,000 |
| Research And Development Expenses | 47,942,000 | 49,732,000 | 57,129,000 |
| General And Administrative Expenses | 47,871,000 | 50,066,000 | 48,271,000 |
| Operating Expenses | 139,128,000 | 142,417,000 | 151,578,000 |
| Operating Income | 7,839,000 | 504,000 | 2,382,000 |
| Net Income | -1,591,000 | -15,545,000 | -9,280,000 |
| Earnings Per Share Basic | -0.02 | -0.16 | -0.1 |
| Earnings Per Share Diluted | -0.02 | -0.16 | -0.1 |
| Weighted Average Shares Outstanding Basic | 102,768,000 | 98,272,000 | 94,884,000 |
| Weighted Average Shares Outstanding Diluted | 102,768,000 | 98,272,000 | 94,884,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 57,416,000 | 68,570,000 | 89,402,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 83,192,000 | 92,001,000 | 74,777,000 |
| Inventories | 141,020,000 | 138,324,000 | 145,150,000 |
| Non Trade Receivables | 841,000 | 368,000 | 10,304,000 |
| Other Assets Current | 6,459,000 | 3,970,000 | 2,483,000 |
| Total Assets Current | 317,465,000 | 323,236,000 | 338,033,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 28,658,000 | 24,774,000 | 20,926,000 |
| Other Assets Non Current | 24,443,000 | 17,950,000 | 20,107,000 |
| Total Assets Non Current | 61,773,000 | 58,547,000 | 141,181,000 |
| Total Assets | 470,239,000 | 468,627,000 | 479,214,000 |
| Accounts Payable | 34,033,000 | 50,020,000 | 33,739,000 |
| Deferred Revenue | 82,306,000 | 71,649,000 | 72,185,000 |
| Short Term Debt | 12,734,000 | 7,756,000 | 5,721,000 |
| Other Liabilities Current | 6,129,000 | 6,311,000 | 7,043,000 |
| Total Liabilities Current | 192,579,000 | 195,267,000 | 198,637,000 |
| Long Term Debt | 136,520,000 | 172,156,000 | 177,283,000 |
| Other Liabilities Non Current | 5,160,000 | 7,389,000 | 4,675,000 |
| Total Liabilities Non Current | 196,491,000 | 228,276,000 | 226,918,000 |
| Total Liabilities | 389,070,000 | 423,543,000 | 425,555,000 |
| Common Stock | 113,000 | 100,000 | 97,000 |
| Retained Earnings | -519,272,000 | -517,681,000 | -502,136,000 |
| Accumulated Other Comprehensive Income | -1,837,000 | -4,222,000 | 422,000 |
| Total Shareholders Equity | 81,169,000 | 45,084,000 | 53,659,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 6,150,000 | 5,905,000 | 4,527,000 |
| Share Based Compensation Expense | 10,201,000 | 9,484,000 | 10,053,000 |
| Other Non Cash Income Expense | 5,124,000 | -11,000 | 135,000 |
| Change In Accounts Receivable | -13,356,000 | 15,826,000 | -18,488,000 |
| Change In Inventories | 9,109,000 | 3,998,000 | 6,855,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -18,674,000 | 17,365,000 | 2,850,000 |
| Change In Other Liabilities | -5,906,000 | -16,506,000 | 887,000 |
| Cash From Operating Activities | 2,860,000 | -11,904,000 | 15,539,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 4,272,000 | 3,601,000 | 12,614,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -8,523,000 | -3,601,000 | -12,681,000 |
| Tax Withholding For Share Based Compensation | 90,000 | 117,000 | 199,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 1,627,000 | 2,247,000 | 2,200,000 |
| Repurchase Of Common Stock | — | — | 0 |
| Issuance Of Long Term Debt | 150,000,000 | — | 0 |
| Repayment Of Long Term Debt | 37,000,000 | 5,000,000 | 0 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -4,252,000 | -3,951,000 | -2,112,000 |
| Change In Cash | -8,258,000 | -20,810,000 | 1,048,000 |
| Cash At End Of Period | 57,416,000 | 68,570,000 | 89,402,000 |
| Income Taxes Paid | 3,870,000 | 1,749,000 | 2,150,000 |
| Interest Paid | 9,737,000 | 10,520,000 | 9,847,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.02 | -0.16 | -0.1 |
| Price To Earnings Ratio | -68.5 | -11 | -38.7 |
| Earnings Growth Rate | -87.5 | 60 | 66.6667 |
| Price Earnings To Growth Ratio | 0.7829 | -0.1833 | -0.5805 |
| Book Value Per Share | 0.7898 | 0.4588 | 0.5655 |
| Price To Book Ratio | 1.7346 | 3.8364 | 6.8432 |
| Ebitda | 21,383,000 | 3,733,000 | 8,029,000 |
| Enterprise Value | 232,630,160 | 284,300,720 | 460,803,080 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 1.8388 | 3.9906 | 3.4105 |
| Capital Expenditures | 10,034,000 | 9,753,000 | 12,768,000 |
| Free Cash Flow | -7,174,000 | -21,657,000 | 2,771,000 |
| Return On Equity | -0.0196 | -0.3448 | -0.1729 |
| One Year Beta | 1.6303 | 1.5938 | 1.3252 |
| Three Year Beta | 1.4934 | 1.3433 | 1.2448 |
| Five Year Beta | 1.3726 | 1.145 | 1.1216 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Le Grand Anne Bryce | Director | 2025-08-29 | 78,947 | A | 78,947 |
| Winter Suzanne C | President and CEO | 2025-06-30 | 16,731 | D | 1,200,047 |
| MAYER STEVEN F | Director | 2025-06-30 | 45,620 | A | 45,620 |
| WHITTERS JOSEPH E | Director | 2025-06-13 | 50,000 | A | 611,053 |
| Pervaiz Ali | SVP Chief Financial Officer | 2025-05-31 | 3,552 | D | 363,679 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| NISA INVESTMENT ADVISORS, LLC | 2025-09-30 | 2,001 | 1,198 | 1.6703 |
| SG Americas Securities, LLC | 2025-09-30 | 58,000 | 34,771 | 1.6681 |
| Crews Bank & Trust | 2025-09-30 | 2,505 | 1,500 | 1.67 |
| North Star Investment Management Corp. | 2025-09-30 | 1,941,074 | 1,162,320 | 1.67 |
| True Wealth Design, LLC | 2025-09-30 | 42 | 25 | 1.68 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Series Total Market Index Fund | FCFMX | 144,502 | 219,643.04 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Total Market Index Fund | FSKAX | 182,900 | 278,008 | 0.0002 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 54,348 | 82,608.96 | 0.0004 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Extended Market Index Fund | FSMAX | 551,230 | 837,869.6 | 0.002 |
| VANGUARD SCOTTSDALE FUNDS | 2025-08-31 | ETF Shares | VTWO | 475,290 | 722,440.8 | 0.0056 |